DK2788761T3 - Reduktion af galectin-3-niveauer ved plasmaferese - Google Patents

Reduktion af galectin-3-niveauer ved plasmaferese Download PDF

Info

Publication number
DK2788761T3
DK2788761T3 DK12855270.0T DK12855270T DK2788761T3 DK 2788761 T3 DK2788761 T3 DK 2788761T3 DK 12855270 T DK12855270 T DK 12855270T DK 2788761 T3 DK2788761 T3 DK 2788761T3
Authority
DK
Denmark
Prior art keywords
gal
cancer
binding molecule
inflammation
use according
Prior art date
Application number
DK12855270.0T
Other languages
English (en)
Inventor
Isaac Eliaz
Original Assignee
Eliaz Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliaz Therapeutics Inc filed Critical Eliaz Therapeutics Inc
Application granted granted Critical
Publication of DK2788761T3 publication Critical patent/DK2788761T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Claims (17)

1. Galectin-3 (gal-3) bindende molekyle til anvendelse i en fremgangsmåde til behandling af (a) cancer; eller (b) fibroser eller (c) skadelig inflammation hos et pattedyr, hvor pattedyret henholdsvis (a) har behov for hæmning af vækst eller spredning af cancer medieret mindst delvist af gal-3; eller (b) har behov for hæmning af udvikling eller ekstension af fibroser medieret af gal-3; eller (c) har behov for hæmning af inflammation medieret af gal-3; hvilken fremgangsmåde omfatter: udførelse af plasmaferese på blodet fra et pattedyr med behov for reduktion af cirkulerende niveauer af gal-3 for at reducere cirkulerende niveauer af aktiv gal-3, hvor plasmaferesen udføres for således selektivt at fjerne gal-3 ved kontakt med det gal-3-bindende molekyle, således at mindst ti procent af den cirkulerende gal-3 i det pågældende individs serum fjernes ved plasmaferesen; hvor det gal-3-bindende molekyle omfatter et gal-3-bindende antistof eller modificeret citruspektin (MCP).
2. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor fremgangsmåden endvidere omfatter periodisk monitorering af niveauet af cirkulerende gal-3 hos pattedyret og gentagelse af plasmaferesen på pattedyret, når niveauet af gal-3 er over et forud valgt niveau af gal-3 for individet, der er konsistent med det pågældende individs gal-3-medierede sygdomstilstand.
3. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor det cirkulerende niveau af gal-3 hos pattedyret er reduceret med mindst femogtyve (25 %).
4. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor det cirkulerende niveau af gal-3 reduceres af plasmaferesen med ca. halvtreds procent (50 %) af niveauet af gal-3 før plasmaferesen.
5. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor individets cirkulerende gal-3-niveau reduceres ved hjælp af fremgangsmåden med mindst femoghalvfjerds procent (75 %).
6. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor trinnet med udførelse af plasmaferese omfatter omledning af en del af pattedyrets blod fra pattedyrets legeme for at tilvejebringe et volumen af separeret blod, fjernelse af røde blodlegemer fra det separerede blod for at tilvejebringe separeret plasma og returnering af de røde blodlegemer til pattedyrets kredsløb, etablering af kontakt mellem det separerede plasma og det gal-3-bindende molekyle, og separering af et hvilket sådant gal-3-bindende molekyle og gal-3-bundet heraf fra resten af det separerede plasma for at tilvejebringe et plasma med reducerede niveauer af gal-3 og returnering af det separerede plasma med reducerede niveauer af gal-3 til pattedyrets kredsløb.
7. Gal-3-bindende molekyle til anvendelse ifølge krav 6, hvor det gal-3-bindende molekyle omfatter et antistof, der binder gal-3, eller hvor det gal-3-bindende molekyle er konjugeret til et element, der gør separationen af det gal-3-bindende molekyle og et hvilket som helst gal-3-bundet heraf det separerede plasma lettere, hvor elementet er en søjle, hvortil det gal-3-bindende molekyle fikseres, et skelet, hvorpå en række af de gal-3-bindende molekyler fikseres, magnetisk tilstrækkelige partikler eller en blanding deraf.
8. Gal-3-bindende molekyle til anvendelse ifølge krav 3, hvor, efter returnering af det separerede plasma til pattedyret, niveauet af cirkulerende gal-3 hos pattedyret er under 15 ng/ml.
9. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor canceren er levercancer, nyrecancer, brystcancer, prostatacancer, coloncancer, thyroideacancer, galdeblærecancer, nasofaryngeal cancer, lymfocytisk leukæmi, lungecancer, melanom, multipelt myelom, glioblastoma multiforme, uteruscancer, ovariecancer, cervix cancer eller hjernecancer.
10. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor pattedyret modtager antineoplastisk kemoterapi mod cancer, hvilken terapi hæmmes af gal- 3.
11. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor fibroserne er forbundet med kardiovaskulær sygdom, gastroenterologisk sygdom, kardiovaskulært traume, hjernetraume, lungetraume, nyrevævstraume, levervævstraume, vævslæsion på grund af stråleterapi eller vævsskade på grund af kemoterapi.
12. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor inflammationen: (a) skyldes farmaceutisk terapi, hvor det farmaceutiske middel fortrinsvis omfatter bleomycin, amidoaron, adriamycin, doxorubicin, cyclophosphamid og cyclosporin; eller (b) er forbundet med ikke-nedbrydelige patogener, autoimmunreaktioner, allergier, ioniserende stråling, nukleær stråling, diabetes, hjertesygdom eller -dysfunktion, aterosklerose; bronkieinflammation; intestinale sår; intestinal tarminflammation; hepatisk inflammation; cirrose-forbundet hepatisk inflammation; inflammation forbundet med parasitinfektion; inflammation forbundet med virusinfektion; inflammation forbundet med svampeinfektion; inflammation forbundet med bakterieinfektion; arthritis-forbundet inflammation; inflammation forbundet med organisk psykiatriske eller hjerneforstyrrelser, multipel sklerose eller psoriasis.
13. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor pattedyret har behov for reduktion af gal-3-niveauer for således at forbedre effektiviteten af et farmaceutisk middel til administration til individet, hvor det farmaceutiske middel fortrinsvis er et statin, et antineoplastisk kemisk middel, et antiinflammatorisk middel, en TNF-blokker eller en TNFa- aktivitetspromoter.
14. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor serummet, før det returneres til individet, blandes med et antineoplastisk middel eller et antiinflammatorisk middel.
15. Gal-3-bindende molekyle til anvendelse ifølge et hvilket som helst af de foregående krav, hvor det gal-3-bindende molekyle er modificeret citruspektin (MCP).
16. Gal-3-bindende molekyle til anvendelse ifølge krav 1, hvor plasmaferesen udføres for således selektivt at fjerne opløselig tumornekrosefaktor- (TNF) receptor i kombination med selektiv fjernelse af gal-3 ved hjælp af plasmaferesen.
17. Gal-3-bindende molekyle til anvendelse ifølge krav 16, hvor TNF-receptoren er R-1 og/eller R-2 og plasmaferesen omfatter flydning af plasmafluid over et leje af TNF-receptorens bindingsmiddel.
DK12855270.0T 2011-12-08 2012-09-28 Reduktion af galectin-3-niveauer ved plasmaferese DK2788761T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568210P 2011-12-08 2011-12-08
PCT/US2012/057749 WO2013085604A1 (en) 2011-12-08 2012-09-28 Reduction of galectin-3 levels by plasmapheresis

Publications (1)

Publication Number Publication Date
DK2788761T3 true DK2788761T3 (da) 2018-04-30

Family

ID=48574756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12855270.0T DK2788761T3 (da) 2011-12-08 2012-09-28 Reduktion af galectin-3-niveauer ved plasmaferese

Country Status (15)

Country Link
EP (2) EP2788761B1 (da)
JP (2) JP6276701B2 (da)
KR (1) KR20140067173A (da)
CN (1) CN104011544B (da)
AU (1) AU2012348311B2 (da)
BR (1) BR112014012823A2 (da)
CA (2) CA3036327C (da)
DK (1) DK2788761T3 (da)
ES (1) ES2669068T3 (da)
IL (1) IL232323A (da)
MX (1) MX355213B (da)
MY (1) MY179044A (da)
RU (1) RU2545859C1 (da)
WO (1) WO2013085604A1 (da)
ZA (2) ZA201402824B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549953B2 (en) 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
CA2893690A1 (en) * 2013-01-07 2014-07-10 Isaac Eliaz Galectin-3 plasmapheresis therapy
US10953148B2 (en) * 2013-12-27 2021-03-23 Eliaz Therapeutics, Inc. Plasmapheresis device
JP2018509994A (ja) * 2015-03-27 2018-04-12 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 患者選択的アフェレシス
CN106370835A (zh) * 2016-08-29 2017-02-01 中山大学孙逸仙纪念医院 皮肤离体样本的免疫组织化学染色检测galectin‑3 辅助诊断银屑病的方法
CN106645752B (zh) * 2016-12-27 2018-02-16 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625212A (en) 1969-07-09 1971-12-07 North American Biolog Inc Eliminating mistakes in plasmapheresis
US4531932A (en) 1981-11-27 1985-07-30 Dideco S.P.A. Centrifugal plasmapheresis device
US6245038B1 (en) 1997-01-07 2001-06-12 Helmut Borberg Method for treatment of ophthalmological diseases
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6462029B1 (en) 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
US6274566B1 (en) 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
EP1617849B1 (en) * 2003-04-07 2008-06-18 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
WO2009086203A2 (en) * 2007-12-27 2009-07-09 Aethlon Medical, Inc. Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment
DE102009030977A1 (de) * 2008-07-14 2010-03-11 Luk Lamellen Und Kupplungsbau Beteiligungs Kg Trockenkupplung
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers

Also Published As

Publication number Publication date
MY179044A (en) 2020-10-26
CN104011544B (zh) 2018-06-05
BR112014012823A2 (pt) 2015-09-29
KR20140067173A (ko) 2014-06-03
ES2669068T3 (es) 2018-05-23
AU2012348311B2 (en) 2014-06-12
CA2858601C (en) 2020-11-17
CA3036327C (en) 2021-10-19
ZA201402824B (en) 2016-09-28
JP2016175925A (ja) 2016-10-06
EP3151009A1 (en) 2017-04-05
ZA201504725B (en) 2018-05-30
JP6276701B2 (ja) 2018-02-07
MX2014006620A (es) 2015-03-05
IL232323A0 (en) 2014-06-30
NZ624601A (en) 2014-09-26
CN104011544A (zh) 2014-08-27
EP2788761A1 (en) 2014-10-15
WO2013085604A1 (en) 2013-06-13
CA3036327A1 (en) 2013-06-13
AU2012348311A1 (en) 2014-05-22
CA2858601A1 (en) 2013-06-13
JP2015507483A (ja) 2015-03-12
EP2788761B1 (en) 2018-02-28
EP2788761A4 (en) 2015-07-15
MX355213B (es) 2018-04-10
JP6248138B2 (ja) 2017-12-13
IL232323A (en) 2015-08-31
RU2545859C1 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
US8764695B2 (en) Reduction of galectin-3 levels by plasmapheresis
DK2788761T3 (da) Reduktion af galectin-3-niveauer ved plasmaferese
US11389477B2 (en) Galectin-3 plasmapheresis therapy
US9649329B2 (en) Binding of galectin-3 by low molecular weight pectin
AU2016262697B2 (en) Galectin-3 plasmapheresis therapy
NZ624601B2 (en) Reduction of galectin-3 levels by plasmapheresis
US20200108092A1 (en) Binding of galectin-3 by low molecular weight pectin
US20180256631A1 (en) Binding of Galectin-3 By Low Molecular Weight Pectin
BR112014012823B1 (pt) Uso de uma molécula de ligação à galectina-3 na preparação de um medicamento para tratar câncer, fibrose ou inflamação